These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 23989175)

  • 1. Sepsis and scientific revolutions.
    Artenstein AW; Higgins TL; Opal SM
    Crit Care Med; 2013 Dec; 41(12):2770-2. PubMed ID: 23989175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is next in sepsis: current trials in sepsis.
    Artigas A; Niederman MS; Torres A; Carlet J
    Expert Rev Anti Infect Ther; 2012 Aug; 10(8):859-62. PubMed ID: 23030324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulatory therapy for sepsis: an update.
    Christaki E; Anyfanti P; Opal SM
    Expert Rev Anti Infect Ther; 2011 Nov; 9(11):1013-33. PubMed ID: 22029521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure of treatments based on the cytokine storm theory of sepsis: time for a novel approach.
    Giamarellos-Bourboulis EJ
    Immunotherapy; 2013 Mar; 5(3):207-9. PubMed ID: 23444949
    [No Abstract]   [Full Text] [Related]  

  • 5. Molecular biology of inflammation and sepsis: a primer.
    Cinel I; Opal SM
    Crit Care Med; 2009 Jan; 37(1):291-304. PubMed ID: 19050640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How could we enhance translation of sepsis immunology to inform immunomodulation trials in sepsis?
    Shankar-Hari M
    Crit Care; 2017 May; 21(1):125. PubMed ID: 28571579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulating the inflammatory response in sepsis.
    Leitman IM
    J Surg Res; 2011 Dec; 171(2):e183-5. PubMed ID: 21962808
    [No Abstract]   [Full Text] [Related]  

  • 8. Critical points for sepsis management at the patient bedside.
    Tulli G
    Minerva Anestesiol; 2003; 69(1-2):35-56, 56-65. PubMed ID: 12677162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Citrulline: a potential immunomodulator in sepsis.
    Asgeirsson T; Zhang S; Nunoo R; Mascarenas C; Dujovny N; Luchtefeld M; Cavey GS; Senagore A
    Surgery; 2011 Oct; 150(4):744-51. PubMed ID: 22000187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dynamics of acute inflammation.
    Kumar R; Clermont G; Vodovotz Y; Chow CC
    J Theor Biol; 2004 Sep; 230(2):145-55. PubMed ID: 15321710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kuhnian revolutions in neuroscience: the role of tool development.
    Parker D
    Biol Philos; 2018; 33(3):17. PubMed ID: 29755159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor for advanced glycation end products in bacterial infection: is there a role for immune modulation of receptor for advanced glycation end products in the treatment of sepsis?
    Christaki E; Lazaridis N; Opal SM
    Curr Opin Infect Dis; 2012 Jun; 25(3):304-11. PubMed ID: 22327468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New perspectives on immunomodulatory therapy for bacteraemia and sepsis.
    Opal SM
    Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S70-3. PubMed ID: 21129935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis.
    Mei SH; Haitsma JJ; Dos Santos CC; Deng Y; Lai PF; Slutsky AS; Liles WC; Stewart DJ
    Am J Respir Crit Care Med; 2010 Oct; 182(8):1047-57. PubMed ID: 20558630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in pathogenesis and management of sepsis.
    Cinel I; Dellinger RP
    Curr Opin Infect Dis; 2007 Aug; 20(4):345-52. PubMed ID: 17609592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sepsis: time has come to focus on the later stages.
    Schefold JC; Hasper D; Volk HD; Reinke P
    Med Hypotheses; 2008 Aug; 71(2):203-8. PubMed ID: 18448264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Surgical sepsis. Part I. Immunologic markers of systemic inflammatory reaction].
    Ostanin AA; Leplina OIu; Tikhonova MA; Zaĭnutdinov IuG; Strel'tsova EI; Ovechkin AV; Chërnykh ER
    Vestn Khir Im I I Grek; 2002; 161(3):101-7. PubMed ID: 12528636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-mobility group box-1 isoforms as potential therapeutic targets in sepsis.
    Parrish W; Ulloa L
    Methods Mol Biol; 2007; 361():145-62. PubMed ID: 17172710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Protein C and coagulation in sepsis].
    D'Angelo A; Della Valle P; Giudici D; Viganò D'Angelo S
    Minerva Anestesiol; 2004 May; 70(5):339-50. PubMed ID: 15181414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CpG oligodeoxynucleotide protection in polymicrobial sepsis is dependent on interleukin-17.
    Rice L; Orlow D; Ceonzo K; Stahl GL; Tzianabos AO; Wada H; Aird WC; Buras JA
    J Infect Dis; 2005 Apr; 191(8):1368-76. PubMed ID: 15776385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.